OncoMatch/Clinical Trials/NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Is NCT06249438 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD20/BCMA-directed CAR-T cells for systemic lupus erythematosus (sle).

Phase 1RecruitingRenJi HospitalNCT06249438Data as of May 2026

Treatment: CD20/BCMA-directed CAR-T cells — This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Check if I qualify

Extracted eligibility criteria

Prior therapy

Min 2 prior lines

Must have received: immunosuppressant

treated with at least two immunosuppressants (including immunosuppressants, biologics, and disease-modifying drug (DMD) )

Cannot have received: CAR-T cell therapy

Previously treated with CAR-T cell products or genetically modified T cell therapies

Cannot have received: bone marrow/hematopoietic stem cell transplantation

bone marrow/hematopoietic stem cell transplantation history

Cannot have received: major organ transplantation

Major organ transplantation history

Lab requirements

Blood counts

Adequate bone marrow function

Kidney function

Adequate renal function

Liver function

Adequate liver function

Cardiac function

Adequate cardiopulmonary function

Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify